Quinoline compound as well as preparation method and application thereof
Through quinoline compounds targeting KRas G12D and some KRas G12V mutations, directly binding and inhibiting gene expression, solving the problem that existing drugs are difficult to treat cerebral arteriovenous malformations with KRAS G12D mutations, achieving better inhibitory effects and avoiding drug resistance.
Patent Information
- Application Number
- CN202410023715.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-06
- Filing Date
- 2024-01-08
- Publication Date
- 2025-07-18
AI Technical Summary
Existing drugs are difficult to effectively target and treat cerebral arteriovenous malformations caused by KRAS G12D mutations, and there are drug resistance problems. Current small molecule drugs cannot bind to the pocket area of KRAS protein, resulting in poor inhibition effect.
A quinoline compound was developed to target KRas G12D and part of KRas G12V mutation locations through electrostatic interactions, and directly bind to KRas G12D and part of KRas G12V, inhibit gene expression and cut off signaling pathways, and avoid drug resistance caused by protein structural changes.
This quinoline compound can effectively inhibit tumors with KRAS G12D mutations, has good preventive and therapeutic effects, is better than the prior art, and can target KRas G12D and some KRas G12V mutations to avoid drug resistance.
Smart Images

Figure CN120329308A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the fields of chemistry and medicine, and particularly relates to a quinoline compound, a preparation method thereof, and an application thereof. Technical Background
[0002] Brain arteriovenous malformation (AVM) is a condition where there is a lack of capillaries between cerebral arteries and cerebral veins at the lesion site, causing the arteries and veins to communicate directly, forming a short circuit between the arteries and veins, leading to a series of disorders in cerebral hemodynamics. It has a high fatality and disability rate and is highly prevalent in people aged 20 - 39. Currently, the treatment methods for brain arteriovenous malformation include surgical resection, interventional embolization, and radiotherapy. However, due to the complex lesion structure, the treatment is extremely difficult and the risk is extremely high, and most lesions cannot be cured.
[0003] CN111568898A discloses a new application of the lipid-lowering drug lovastatin in brain arteriovenous malformation, which can inhibit the mesenchymal transformation of endothelial cells and enhance the stability of endothelial cells, thereby reducing the possibility of rupture and bleeding of brain arteriovenous malformation. However, this drug only reduces the bleeding symptoms caused by brain arteriovenous malformation and cannot truly treat brain arteriovenous malformation. CN111658647A discloses a new use of the glutamate derivative thalidomide in the treatment of arteriovenous malformation. By oral administration, the lesion size of the patient is reduced; however, since the patient had undergone embolization twice before, it is impossible to determine that this effect is due to thalidomide. In addition, from the attached drawings, it can be seen that the effect of this drug on the treatment of arteriovenous malformation is limited and there are other adverse complications.
[0004] Brain arteriovenous malformation is divided into two major categories, namely sporadic arteriovenous malformation and familial arteriovenous malformation. Among them, sporadic arteriovenous malformation has a larger lesion volume and a higher bleeding rate. Through existing research, it has been found that more than 90% of sporadic arteriovenous malformations have mutations in KRas and its downstream genes, and the literature points out (Park ES, et al. Ann Neurol. 2021 May; 89(5): 926 - 941) that virus-mediated overexpression of KRas is involved in the formation of AVM, and this phenomenon is particularly obvious in large aneurysms; and using trametinib to block the MEK / ERK pathway downstream of KRas can effectively inhibit the growth of AVM. However, due to the widespread mutations in the KRas gene and its downstream genes in AVM, for the mutated KRas gene and its downstream gene mutations, trametinib, which mainly targets the MEK protein (the upstream regulator of the extracellular signal-related kinase (ERK) pathway), will develop strong drug resistance and lose its therapeutic effect.
[0005] Currently, for the KRas gene, the drugs that have been approved by the FDA for marketing are Sotorasib and Adagrasib. However, both of these drugs are protein inhibitors targeting KRas G12C. Once the KRas protein undergoes allosteric changes, small molecule drugs cannot bind to the pocket region of the protein, losing their inhibitory effect on the KRas protein.
[0006] More importantly, after the KRAS gene mutates, the protein remains in an activated state continuously, leading to the continuous activation of downstream signaling pathways and promoting tumorigenesis. Due to the lack of traditional small molecule binding sites on the surface of the KRAS protein and its extremely high affinity for guanosine nucleotides, it is extremely difficult to be inhibited. However, due to the importance of abnormal KRAS activation in cancer progression and the universality of KRAS gene mutations in human cancers, KRAS has always been and still is a very concerned target for drug development. Although progress has been made in targeting KRAS G12D, it is still a challenge to target this gene with small molecules. Therefore, developing inhibitors of KRAS, especially inhibitors of KRAS G12D, has very important clinical significance in this field. At the same time, it is also very meaningful to develop a drug that can accurately target the KRas gene of cerebral arteriovenous malformations and effectively treat cerebral arteriovenous malformations. Summary of the Invention
[0007] In view of the above limitations, the present application proposes a novel quinoline compound; it has excellent inhibitory activity against tumors with KRAS G12D mutations and has great potential application prospects in the field of tumors. Moreover, for cerebral arteriovenous malformations caused by mutations in KRAS G12D and some KRAS G12V, it can inhibit the generation of cerebral arteriovenous malformations at the gene level and avoid the occurrence of drug resistance; and this compound can target the mutation positions of KRAS G12D and some KRAS G12V; avoiding the problems of inability to target and treat caused by this mutation, and overcoming the deficiencies and defects mentioned in the background art.
[0008] To achieve the above object, the present application adopts the following technical solutions:
[0009] The invention point of the present application is to provide a quinoline compound, which includes at least one of the chemical formulas shown in Formula I, and its pharmaceutically acceptable salts:
[0010]
[0011] Among them, R 1 、R 3 and R 4independently includes H, halogen, oxygen-containing group, nitrogen-containing group, phosphorus-containing group, sulfur-containing group or carbon-containing unsaturated bond; R2 includes C1-C 10 alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl, C3-C 10 cycloalkyl, C2-C 10 heterocycloalkyl, C6-C 10 aryl or C5-C 10 heteroaryl, and any hydrogen-containing atom in the R 2 can be connected to the oxygen atom in Formula I, including the substituents in the R 2 , which can also be connected to the oxygen atom. For example, if the R 2 is a six-membered cycloalkane and the substituent on the R 2 is a methyl group, then not only any atom on the six-membered cycloalkane can be connected to the O atom, but also the methyl group connected thereto can be connected to the O atom.
[0012] Optionally, the oxygen-containing group includes hydroxyl, ether, carboxyl, ester, acyl halide, aldehyde or ketone group; the nitrogen-containing group includes amino, cyano, imino, nitro, amide or cyanate group; the phosphorus-containing group includes phosphino, phosphoric acid, phosphate, phosphorous acid or phosphite group; the sulfur-containing group includes mercapto, thioether, sulfonic acid, sulfonate or disulfide bond.
[0013] Optionally, R 1 is selected from halogen; R 3 is selected from halogen or oxygen-containing group; R 4 is selected from hydrogen, oxygen-containing group or nitrogen-containing group; R 2 is selected from C3-C 10 cycloalkyl with or without substituents or C2-C 10 heterocycloalkyl.
[0014] Optionally, the number of R 1 , R 2 , R 3 and R 4 can be one or more; when there are multiple R 1 , the multiple R 1 are completely the same, partially the same or completely different.
[0015] Optionally, the R 1 is F or Cl; the R2 is C5-C6 cycloalkyl with or without substituents or C5-C6 heterocycloalkyl, preferably, the R2 is The R 3 is at least one of OH, alkynyl, Cl.
[0016] Optionally, when there are multiple R1s, the multiple R1s are completely identical; when there are multiple R3s, the multiple R3s are completely different.
[0017] Optionally, the quinoline compounds include:
[0018] The pharmaceutically acceptable salts of the compounds are salts formed by the reaction of the compounds with acids or bases. The acids are hydrochloric acid, hydrobromic acid, carbonic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, malic acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid or mandelic acid; the bases are inorganic bases or organic amines containing alkaline metal cations, alkaline earth metal cations or ammonium cation salts.
[0019] Another inventive point of the present application is to provide a preparation method of any of the above-mentioned quinoline compounds.
[0020] The preparation method includes:
[0021] (1) React to generate
[0022] (2) React with first to generate and then react with to generate Or react with first to generate and then react with to generate
[0023] (3) Remove the R 5 group under acidic or basic conditions to generate the quinoline compound;
[0024] wherein, X is a halogen, preferably bromine or iodine; R 5 is an amino protecting group, preferably selected from tert-butoxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc); R 6 is selected from hydrogen, methyl or two R 6 are connected to the corresponding oxygen or boron atom to form a 5- to 6-membered ring, such as
[0025] Another inventive point of the present application is to provide a preparation, including any of the above-mentioned quinoline compounds.
[0026] Another inventive point of the present application is to provide an application of the above-mentioned preparation in the preparation of drugs for treating cerebral arteriovenous malformations.
[0027] Another inventive point of the present application is to provide a use of the quinoline compound or a pharmaceutically acceptable salt thereof for preparing a KRAS G12D inhibitor and for preparing a drug for treating diseases related to KRAS G12D gene mutation.
[0028] Preferably, the diseases are selected from pancreatic cancer, non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, colon cancer, colorectal cancer, thyroid cancer, embryonal rhabdomyosarcoma, cutaneous granular cell tumor, melanoma, liver cancer, rectal cancer, bladder cancer, throat cancer, breast cancer, prostate cancer, glioblastoma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, kidney cancer, skin cancer, lymphoma, gastric cancer, acute myeloid leukemia, myelofibrosis, B-cell lymphoma, monocytic leukemia, splenomegalic polycythemia, eosinophilic leukocytosis syndrome, multiple myeloma and other various solid tumors and hematological tumors with KRAS G12D gene mutation.
[0029] Compared with the prior art, the present application has the following advantages:
[0030] The quinoline compound of the present application can specifically target the mutation sites of KRas G12D and partial KRas G12V through electrostatic interaction, bind to them, inhibit the expression of this gene, and further inhibit the cerebral arteriovenous malformation caused by this gene; in addition, since this gene is extremely prone to mutation and cause protein structure changes, and the compound of the present application directly binds to KRasG12D and partial KRas G12V, fundamentally cutting off the signal pathway caused by this gene; it can further avoid the drug resistance problem caused by protein structure changes.
[0031] More importantly, the compound in the present invention has good inhibitory activity on tumors with KRAS G12D mutation, has good preventive and therapeutic effects, and has a more excellent inhibitory effect than the prior art. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 It is a cell killing curve graph of Compound V provided in Test Example 1 of the present application; the abscissa is the cell concentration, with the unit of μM; the ordinate is the optical density value, with the unit of OD;
[0033] Figure 2 It is a cell killing curve graph of Sotorasib provided in Comparative Example 2 of the present application; the abscissa is the cell concentration, with the unit of μM; the ordinate is the optical density value, with the unit of OD;
[0034] Figure 3It is the concentration-inhibition rate curve of mrtx1133 for AGS cells (gastric adenocarcinoma cells); the abscissa is Log[compound concentration] with the unit of μM; the ordinate is the inhibition rate with the unit of %.
[0035] Figure 4 It is the concentration-inhibition rate curve of compound V provided in Test Example 1 of this application for AGS cells; the abscissa is Log[compound concentration] with the unit of μM; the ordinate is the inhibition rate with the unit of %.
[0036] Figure 5 It is the concentration-inhibition rate curve of compound VI provided in Test Example 2 of this application for AGS cells; the abscissa is Log[compound concentration] with the unit of μM; the ordinate is the inhibition rate with the unit of %.
[0037] Figure 6 It is the concentration-inhibition rate curve of compound VII provided in Test Example 3 of this application for AGS cells; the abscissa is Log[compound concentration] with the unit of μM; the ordinate is the inhibition rate with the unit of %.
[0038] Figure 7 It is the curve of the binding inhibition activity of compound VIII provided in Test Example 4 of this application with KRAS G12D: the abscissa is Log[compound concentration] with the unit of nM, and the ordinate is the ratio (665 / 620) with the unit of %.
[0039] Figure 8 It is the curve of the binding inhibition activity of compound IX provided in Test Example 5 of this application with KRAS G12D: the abscissa is Log[compound concentration] with the unit of nM, and the ordinate is the ratio (665 / 620) with the unit of %. Detailed implementation manners
[0040] To make the purpose, technical solutions and advantages of this application clearer, the following further details this application. However, it should be understood that the description herein is only used to explain this application and does not limit the scope of this application.
[0041] Unless otherwise defined, all technical terms and scientific terms used herein have the same meaning as commonly understood by those skilled in the technical field to which this application belongs. The terms used in the description of this application in this specification are only for the purpose of describing specific embodiments and are not intended to limit this application. The reagents and instruments used herein are all commercially available, and the related characterization means can be referred to the relevant descriptions in the prior art and will not be elaborated herein.
[0042] To further understand this application, the following further details this application in combination with the best embodiments.
[0043] Example 1
[0044] This example provides a quinoline compound, and the quinoline compound includes at least one of the chemical formulas shown in Formula I,
[0045]
[0046] wherein, when the mother nucleus is a quinoline mother nucleus, i.e., the structural formula is R 1 R 3 and R 4 independently include H, halogen, oxygen-containing group, nitrogen-containing group, phosphorus-containing group, sulfur-containing group or carbon-containing unsaturated bond; R2 includes C1-C 10 alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl, C3-C 10 cycloalkyl, C2-C 10 heterocycloalkyl, C6-C 10 aryl or C5-C 10 heteroaryl with or without substituents, and any hydrogen-containing atom in this R 2 can be connected to the oxygen atom in Formula I, including the substituents in R 2 which can also be connected to the oxygen atom.
[0047] The oxygen-containing group includes a group containing oxygen element, which can be an oxygen-containing functional group or an alkyl, hydrocarbon, alkynyl or aryl group containing oxygen, etc. The oxygen-containing functional group can be hydroxyl, ether group, carboxylate, carboxyl group, carbonate group, ester group, peroxy group, acyl halide group, aldehyde group or ketone group; the alkyl, hydrocarbon, alkynyl or aryl group containing oxygen can be an alkyl, hydrocarbon, alkynyl or aryl group with an oxygen-containing functional group. Other heteroatoms can also exist in the alkyl, hydrocarbon, alkynyl or aryl group containing oxygen; the other heteroatoms include nitrogen, phosphorus, sulfur, etc., which can form a certain structure with the oxygen atom, form a functional group, or exist alone without combining with oxygen.
[0048] The oxygen-containing group is preferably hydroxyl, ether group, carboxyl group, ester group, acyl halide group, aldehyde group or ketone group.
[0049] The nitrogen-containing group includes amino group, cyano group, imino group, nitro group, amide group or cyanate group; the phosphorus-containing group includes phosphorus group, phosphoric acid group, phosphate group, phosphorous acid group or phosphite group; the sulfur-containing group includes mercapto group, thioether group, sulfonic acid group, sulfonate group or disulfide bond. Halogen includes fluorine, chlorine, bromine, iodine, astatine.
[0050] The carbon-containing unsaturated bond includes ester group, carboxylic acid group, aldehyde group, ketone group, cyano group, acyl group, alkynyl group or alkenyl group; preferably alkynyl group, aldehyde group, carboxylic acid group, acyl group, which can form hydrogen bonds,
[0051] R1 R3 is selected from halogen; R3 is selected from halogen, an oxygen-containing group or an unsaturated carbon-carbon bond; R 4 is selected from hydrogen, an oxygen-containing group or a nitrogen-containing group.
[0052] Preferably, R 1 is selected from fluorine, chlorine, bromine.
[0053] Preferably, R 3 is selected from fluorine, chlorine, bromine, hydroxyl group, alkynyl group, acyl group, aldehyde group, carboxylic acid group or alkynyl group.
[0054] Preferably, R 4 is selected from hydrogen.
[0055] R 2 is selected from C3-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, C4-C8 cycloalkyl, C3-C8 heterocycloalkyl, C6-C8 aryl or C5-C8 heteroaryl with or without substituents; preferably, R 2 is selected from C3-C 10 cycloalkyl or C2-C 10 heterocycloalkyl; more preferably, R 2 is selected from C4-C8 cycloalkyl or C3-C8 heterocycloalkyl with or without substituents.
[0056] Preferably, R 2 is selected from a four-membered ring, five-membered ring, six-membered ring, seven-membered ring, eight-membered ring, four-membered heterocycle, five-membered heterocycle, six-membered heterocycle or seven-membered heterocycle with or without substituents.
[0057] The heterocycloalkyl contains heteroatoms; the heteroatoms include oxygen atom, nitrogen atom, phosphorus atom or sulfur atom. Preferably, the heteroatom is oxygen atom or nitrogen atom.
[0058] Preferably, R 2 is selected from furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyrrole, dihydropyrrole, tetrahydropyrrole, oxazole, thiazole, imidazole, pyrazole, pyridine, pyrimidine, pyran, cyclohexane, cyclopentane, cycloheptane, cyclohexene, cyclopentene, cycloheptene.
[0059] Preferably, R 2 may also be selected from furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyrrole, dihydropyrrole, tetrahydropyrrole, oxazole, thiazole, imidazole, pyrazole, pyridine, pyrimidine, pyran, cyclohexane, cyclopentane, cycloheptane, cyclohexene, cyclopentene, cycloheptene with substituents.
[0060] The substituent is preferably halogen, specifically fluorine, chlorine, bromine; more preferably fluorine.
[0061] Preferably, R 2 is also optionally selected from halogen-containing furan, dihydrofuran, tetrahydrofuran, thiophene, dihydrothiophene, tetrahydrothiophene, pyrrole, dihydropyrrole, tetrahydropyrrole, oxazole, thiazole, imidazole, pyrazole, pyridine, pyrimidine, pyran, cyclohexane, cyclopentane, cycloheptane, cyclohexene, cyclopentene, cycloheptene.
[0062] The number of halogens can be 1 to 10, for example, it can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0063] When there are at least two halogens, the specific selection of halogens can be the same or different; preferably, multiple halogens are the same.
[0064] Preferably, multiple halogen substitutions are carried out on the same C, for example wherein X is a halogen. Among multiple Xs, the specific selection of X can be the same or different. For example, in , X can be F and Cl respectively, or both can be F or both can be Cl; preferably, Xs are all F.
[0065] Substituents include those substituted by halogen, OH, CN, NH2, C1-C6 alkyl, C1-C6 alkoxy, C2-C 10 alkenyl, C2-C 10 alkynyl, C3-C 10 cycloalkyl, C1-C 10 heterocycloalkyl, aryl or heteroaryl. Preferably, substituents include those substituted by halogen, OH, CN, NH2, and more preferably, the substituent is halogen.
[0066] Preferably, the structure of R 2 includes
[0067] R 1 、R 2 、R 3 and R 4 The number of them can be one or more.
[0068] When there are multiple Rs 1 , multiple Rs 1 can be completely the same, partially the same or completely different. For example, when formula I contains 3 Rs 1 , they are respectively named as R 11 , R 12 , R 13 , wherein, R 11 , R 12 and R 13 can select different groups or the same group, that is, R 11 =R 12 =R13 and (R 11 = R 12 ) ≠ R 13 , R 11 ≠ (R 12 = R 13 ), R 11 ≠ R 12 ≠ R 13 and (R 11 = R 13 ) ≠ R 12 .
[0069] R 2 , R 3 and R 4 are similar to R 1 specifically, when there are multiple Rs 2 , the multiple Rs 2 can be completely identical, partially identical, or completely different. For example, when formula I contains 3 Rs 2 , they are respectively named R 21 , R 22 , R 23 , where R 21 , R 22 and R 23 can select different groups or the same group, that is, R 21 = R 22 = R 23 , (R 21 = R 22 ) ≠ R 23 , R 21 ≠ (R 22 = R 23 ), R 21 ≠ R 22 ≠ R 23 , (R 21 = R 23 ) ≠ R 22 ; when there are multiple Rs 3 , the multiple Rs 3 can be completely identical, partially identical, or completely different. For example, when formula I contains 3 Rs 3 , they are respectively named R 31 , R 32 , R 33 , where R 31 , R 32 and R 33 can select different groups or the same group, that is, R 31 = R 32 = R 33 , (R 31 = R 32 ) ≠ R 33 , R31 ≠(R 32 =R 33 )、R 31 ≠R 32 ≠R 33 、(R 31 =R 33 )≠R 32 。
[0070] Preferably, when there are multiple Rs 1 , the multiple Rs 1 are exactly the same.
[0071] Preferably, when there are multiple Rs 3 , the multiple Rs 3 are completely different.
[0072] R 1 can replace any one or more of the hydrogens connected to carbon in the quinoline group. Specifically, as shown in Formula II, R 1 can be located at a1, b1, c1, and d1 of the quinoline group; when there is only one R 1 , it can be located at any one of a1, b1, c1, and d1; when there are two Rs 1 , that is, R 11 and R 12 , they can be a1 and b1, a1 and c1, a1 and d1, b1 and c1, b1 and d1, c1 and d1 respectively; when there are three Rs 1 , that is, R 11 , R 12 , R 13 , they are located at a1 and b1 and c1, a1 and b1 and d1, a1 and c1 and d1, b1 and c1 and d1 respectively; when there are four Rs 1 , that is, R 11 , R 12 , R 13 , R 14 , they can only be located at a1, b1, c1, and d1 respectively, and there is no other choice; therefore, the maximum number of Rs 1 in the quinoline group is four.
[0073]
[0074] Preferably, the number of Rs 1 in the quinoline group is two, and the positions of R 11 and R 12 are not adjacent (not located at b1 and c1), that is, they can be a1 and b1, a1 and c1, a1 and d1, b1 and d1, c1 and d1 respectively; more preferably, R 11 and R 12 are located at c1 and d1 respectively.
[0075] R 3 Any one or more of the hydrogens connected to carbon in the naphthyl group can be replaced. Specifically, as shown in Formula III, R 1 can be located at a3, b3, c3, d3, e3, f3, and g3 of the quinolinyl group; when there is only one R3, it can be located at any one of a3, b3, c3, d3, e3, f3, and g3; when there are two Rs 3 i.e., R 31 and R 32 , they can be any two of a3, b3, c3, d3, e3, f3, and g3 respectively; when there are three Rs 3 i.e., R 31 , R 32 , R 33 , they are located at any three of a3, b3, c3, d3, e3, f3, and g3 respectively; when there are seven Rs 3 i.e., R 3 , they can only be located at a3, b3, c3, d3, e3, f3, and g3 respectively; therefore, the maximum number of Rs
[0076]
[0077] Preferably, the number of Rs 3 in the naphthyl group is two, i.e., R 31 and R 32 , which can be any two of a3, b3, c3, d3, e3, f3, and g3 respectively; preferably, R 31 and R 32 are located in different benzene rings, i.e., R 31 is located at a3, b3, c3, and R 32 is located at d3, e3, f3, and g3.
[0078] R 4 Any one or more of the hydrogens connected to carbon or nitrogen in the bridged ring can be replaced. Specifically, as shown in Formula IV, R 4 can be located at a4, b4, c4, d4, e4, and f4 of the quinolinyl group; when there is only one R 4 , it can be located at any one of a4, b4, c4, d4, e4, and f4; when there are two Rs 4 i.e., R 41 and R 42 , they can be any two of a4, b4, c4, d4, e4, and f4 respectively; when there are three Rs 4 i.e., R 41 , R 42 , R 43, located at any three of a4, b4, c4, d4, e4 and f4 respectively; wherein the hydrogens of a4, c4, d4 and f4 can be replaced by two R 4 substitutions, so the maximum number of R 4 in the bridged ring is eleven.
[0079]
[0080] Preferably, the quinoline compound includes:
[0081] In this application, through preliminary research, it is found that the mother nucleus of this compound also has a great influence on its inhibitory activity. Therefore, when the mother nucleus changes, the inhibitory effect of this compound may change greatly.
[0082] Example 2
[0083] This example provides a preparation method of a quinoline compound, which is the same as the quinoline compound described in Example 1 and will not be elaborated here.
[0084] The preparation method includes: (1) React to generate (2) React with first to generate and then react with to generate Or react with first to generate and then react with to generate (3) Remove the R 5 group under acidic or basic conditions to generate the quinoline compound; wherein, X is a halogen, preferably bromine or iodine; R 5 is an amino protecting group, preferably selected from tert-butoxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc); R 6 is selected from hydrogen, methyl or two R 6 connected to the corresponding oxygen or boron atom to form a 5-6 membered ring, such as
[0085] Example 3
[0086] This example provides a preparation, including any one of the above-mentioned quinoline compounds.
[0087] The preparation also includes pharmaceutically acceptable excipients.
[0088] The preparation can be prepared by selecting pharmaceutically acceptable common excipients, using conventional dosages and adopting conventional preparation methods.
[0089] The excipients described in the present application may vary according to different preparations, such as surfactants, diluents, preservatives, stabilizers, flavoring agents, thickeners, glidants, etc. commonly used in liquid preparations such as oral liquids; diluents, disintegrants, excipients, binders, lubricants, surfactants, fillers, etc. commonly used in solid preparations such as tablets, capsules, granules, etc.
[0090] The auxiliary material is selected from at least one of starch, lactose, sucrose, dextrin, maltodextrin, microcrystalline cellulose, mannitol, xylitol, polyethylene glycol, calcium carbonate, modified starch, sorbitol, sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethyl cellulose, sodium carboxymethyl starch, hydroxypropyl cellulose, povidone K30, pregelatinized starch, magnesium stearate, talc, micropowder silica gel, stevioside, betaine, aspartame, citric acid, green tea sweetener, sodium saccharin, crystal sugar, honey, citric acid, sodium bicarbonate, sodium carbonate, carrageenan, agar, gelatin, sodium alginate, xanthan gum, guar gum, tragacanth gum, gum arabic, locust bean gum, stearic acid, cross-linked sodium polyacrylate, polyvinyl alcohol, carbomer, sorbic acid, potassium sorbate, ethyl hydroxybenzoate, benzyl alcohol, glycerin, and propylene glycol.
[0091] The preparation is in the form of decoction, granules, capsules, tablets, chewable tablets, oral liquid, pills, tincture, syrup, suppository, gel, spray or injection.
[0092] Example 4
[0093] This embodiment provides an application of the above-mentioned preparation in the preparation of a drug for treating cerebral arteriovenous malformation. The preparation is the same as the preparation described in Example 5, and will not be described in detail here.
[0094] The cerebral arteriovenous malformation may be a sporadic arteriovenous malformation or a familial arteriovenous malformation; preferably, it is a sporadic arteriovenous malformation.
[0095] This embodiment provides a use of the above-mentioned quinoline compound or a pharmaceutically acceptable salt thereof for preparing a KRASG12D inhibitor, and a use thereof for preparing a drug for a disease associated with a KRAS G12D gene mutation.
[0097] Example 5
[0098] According to the content of this application, the quinoline compound of Example 1 and the preparation method of Example 2, the preparation of Example 3, and the application of Example 4 are specifically described, and the specific description is as follows:
[0099] Test Example 1
[0100] Intermediate 1
[0101]
[0102] Step A: 3-Bromo-2-fluoroaniline (10 g, 52.6 mmol, 1.0 eq) was dissolved in dichloromethane (100 mL), triethylamine (8.8 mL) was added, and the mixture was cooled in an ice bath. A solution of ethyl 3-chloro-3-oxopropionate (CAS: 36239-09-5) (5.90 mL, 63.2 mmol, 1.2 eq) in dichloromethane (50 mL) was slowly added dropwise. After the addition, the mixture was allowed to warm to room temperature and react for 2 h. The reaction mixture was added with water (100 mL), and then extracted three times with 100 mL of dichloromethane each time. The combined organic phases were washed with saturated sodium bicarbonate solution (100 mL). The organic phase was concentrated to obtain a crude product as an orange-red solid mass. The crude product was dissolved in tetrahydrofuran (60 mL), and an aqueous solution (30 mL) of lithium hydroxide monohydrate (8.85 g, 210.44 mmol, 4.0 eq) was added. The mixture was stirred at room temperature for 3 h. Then the reaction mixture was rotary evaporated to remove tetrahydrofuran, ethyl acetate (20 mL) was added, and it was washed three times with saturated sodium bicarbonate solution (20 mL) again. The aqueous phase was taken, and the pH was adjusted to 1-2 with 1N dilute hydrochloric acid, a large amount of white solid was precipitated, filtered by suction, the obtained filter cake was washed with ice water, and then dried by infrared to obtain the product 3-[(3-bromo-2-fluorophenyl)amino]-3-oxopropanoic acid as a white solid, 9.01 g, with a yield of 62%. 1 HNMR(300MHz,Chloroform-d)δ9.09(s,1H),8.25(t,J=7.8Hz,1H),7.41-7.31(m,1H),7.07(t,J=8.3Hz,1H),3.62(s,2H).
[0103] Step B: 3-[(3-Bromo-2-fluorophenyl)amino]-3-oxopropanoic acid (2.0 g, 36.2 mmol, 1.0 eq) was mixed with Eaton's reagent (CAS: 39394-84-8) (3 mL), and the mixture was heated and stirred at 70 °C for 5 h. After the reaction mixture was cooled, ice water (10 mL) was added, filtered by suction, and the filter cake was washed with ice water to obtain the product 7-bromo-8-fluoro-4-hydroxy-1,2-dihydroquinolin-2-one as a light yellow solid, 1.75 g, with a yield of 56%. 11H NMR (300 MHz, Chloroform-d) δ 8.43 (s, 1H), 8.24 (ddd, J = 8.4, 7.0, 1.6 Hz, 1H), 7.39 (ddd, J = 8.1, 6.5, 1.6 Hz, 1H), 7.10 (td, J = 8.3, 1.6 Hz, 1H), 6.09 (s, 1H).
[0104] Step C: Dissolve 7-bromo-8-fluoro-4-hydroxy-1,2-dihydroquinolin-2-one (2.0 g, 7.75 mmol, 1.0 eq) in phosphorus oxychloride (16.62 mL, 178.26 mmol, 23.0 eq), add N,N-diisopropylethylamine (6.75 mL, 38.75 mmol, 5.0 eq), and reflux the reaction mixture at 100 °C for 8 h. Spin-dry the reaction mixture, pour it into ice, extract with dichloromethane (20 mL × 3), spin-dry the organic phase to obtain a dark brown solid, and purify it by column chromatography (petroleum ether:ethyl acetate = 15:1) to obtain Intermediate 1 as a pale yellow solid, 1.6 g, with a yield of 72%. 1 1H NMR (300 MHz, Chloroform-d) δ 7.91 (d, J = 9.1 Hz, 1H), 7.79 (dd, J = 9.1, 5.9 Hz, 1H), 7.62 (s, 1H). EI-MS m / z: 293.90 [M+H] + .
[0105] Intermediate 2
[0106] Dissolve Intermediate 1 (1.0 g, 3.39 mmol, 1.0 eq) and N,N-diisopropylethylamine (3.54 mL, 23.73 mmol, 7.0 eq) in CH3CN (15 mL), add 8-Boc-3,8-diazabicyclo[3.2.1]octane (791.84 mg, 3.73 mmol, 1.1 eq), and stir the reaction mixture at room temperature for 48 h. Add water (15 mL) to the reaction mixture, then extract it three times with 15 mL of dichloromethane each time. Concentrate the organic phase and purify it by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain Product Intermediate 2 as a white solid, 817 mg, with a yield of 51%. 1 1H NMR (300 MHz, Chloroform-d) δ 7.63 (dd, J = 9.0, 1.5 Hz, 1H), 7.36 (dd, J = 8.9, 6.0 Hz, 1H), 7.05 (s, 1H), 4.41 (s, 2H), 3.28 (s, 2H), 2.03 - 1.93 (m, 2H), 1.76 (d, J = 8.9 Hz, 4H), 1.49 (s, 10H). EI-MS m / z: 470.08 [M+H] + .
[0107] Intermediate 3
[0108] (R)-(-)-1-BOC-3-hydroxypyrrolidine (96.26 mg, 0.514 mmol, 1.1 eq) was mixed with sodium hydride (162.15 mg, 4.673 mmol, 15 eq) in N,N-dimethylformamide (3 mL). After stirring at room temperature for 1 h, a solution of Intermediate 2 (220 mg, 0.467 mmol, 1.0 eq) in N,N-dimethylformamide (7 mL) was added thereto, and the mixture was stirred at 70 °C for 5 h. Water (10 mL) was added to the reaction mixture, and then it was extracted three times with 15 mL of ethyl acetate each time, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain Intermediate 3 as a white solid powder, 221 mg, with a yield of 42%. 1 H NMR (400 MHz, Chloroform-d) δ 7.55 (dd, J = 8.8, 1.5 Hz, 1H), 7.24 (dd, J = 8.9, 6.0 Hz, 1H), 6.14 (s, 1H), 5.10 (s, 1H), 4.41 (d, J = 7.3 Hz, 3H), 3.77 (s, 1H), 3.74 - 3.49 (m, 3H), 2.28 (d, J = 32.4 Hz, 2H), 1.99 (dd, J = 9.0, 4.6 Hz, 2H), 1.89 - 1.72 (m, 2H), 1.50 (s, 9H), 1.49 (s, 9H). EI-MS m / z: 621.24 [M+H] + .
[0109] Intermediate 4
[0110] Intermediate 3 (190 mg, 0.3 mmol, 1.0 eq) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol (CAS: 2043962-01-0) (90 mg, 0.33 mmol, 1.1 eq), potassium carbonate (120 mg, 0.9 mmol, 3 eq) were dissolved in dioxane (10 mL). Tetrakis(triphenylphosphine)palladium (20 mg, 15 μmol, 0.05 eq) and water (2 mL) were added successively, and the mixture was heated to 100 °C under nitrogen protection for 5 h. The reaction mixture was quenched with water (50 mL), extracted three times with 50 mL of ethyl acetate each time, the organic phases were combined, concentrated, and separated by column chromatography (petroleum ether:ethyl acetate = 3:2) to obtain the product Intermediate 4 as a white solid, 60 mg, with a yield of 28%. 11H NMR (400 MHz, DMSO-d6) δ 9.79 - 9.72 (m, 1H), 7.78 - 7.66 (m, 2H), 7.46 - 7.31 (m, 2H), 7.16 (d, J = 2.5 Hz, 2H), 7.12 - 7.05 (m, 1H), 7.01 (dd, J = 9.0, 3.9 Hz, 1H), 6.64 (s, 1H), 5.76 (s, 2H), 4.28 (s, 4H), 3.93 (s, 1H), 3.68 (s, 1H), 3.64 - 3.45 (m, 3H), 3.10 (t, J = 15.6 Hz, 4H), 2.24 (d, J = 15.6 Hz, 3H), 1.88 (s, 2H), 1.73 (s, 3H), 1.44 (s, 9H), 1.43 - 1.38 (m, 9H), 1.33 (d, J = 2.7 Hz, 4H), 1.29 - 1.22 (m, 6H). EI-MS m / z: 685.83 [M + H] + .
[0111] Compound V
[0112] Intermediate 4 (100 mg, 0.146 mmol, 1.0 eq) was dissolved in hydrochloric acid - methanol solution (5 mL), and stirred at room temperature for 12 h. The reaction solution was concentrated under reduced pressure, filtered by suction. The filter cake was dissolved in methanol (2 mL), saturated sodium bicarbonate solution (5 mL) was added, and then filtered by suction. The filter cake was washed with ice water and dried by infrared to obtain Compound V as a white solid, 42.3 mg, with a yield of 60%. 1 1H NMR (400 MHz, DMSO-d6) δ 9.90 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.43 (ddd, J = 8.2, 6.7, 1.3 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), 7.28 - 7.17 (m, 3H), 7.11 (d, J = 2.4 Hz, 1H), 6.81 (s, 1H), 5.61 (q, J = 3.6 Hz, 1H), 4.46 (d, J = 13.4 Hz, 2H), 4.22 - 4.16 (m, 2H), 3.68 - 3.51 (m, 2H), 3.42 (t, J = 17.6 Hz, 4H), 2.33 (ddd, J = 10.1, 6.8, 3.4 Hz, 2H), 2.02 (dd, J = 9.0, 4.2 Hz, 2H), 1.87 (q, J = 6.6, 5.7 Hz, 2H). HRMS (ESI): calcd for C 29 H 29 F4N4O2 [M + H] +485.2347, found 485.2342.
[0113] Test Example 2
[0114] Intermediate 5
[0115]
[0116] Step A: Dissolve 3-bromo-2,4-difluoroaniline (6.24 g, 30 mmol, 1.0 eq) in dichloromethane (20 mL), add triethylamine (5 mL, 36 mmol, 1.2 eq), and dropwise add a solution of ethyl 3-chloro-3-oxopropionate (4.6 mL, 36 mmol, 1.2 eq) in dichloromethane (50 mL) under an ice bath. After the addition is complete, warm the reaction mixture to room temperature and react for 2 h. After the reaction is complete, add water (50 mL) to quench the reaction, separate the organic phase, wash it with saturated sodium bicarbonate solution (50 mL × 3), concentrate the organic phase to obtain a crude product as an orange-red solid mass. Dissolve it in tetrahydrofuran (30 mL), add an aqueous solution (20 mL) of lithium hydroxide monohydrate (1.85 g, 45 mmol, 1.5 eq), and stir at room temperature for 3 h. After the reaction mixture is rotary evaporated to remove tetrahydrofuran, add ethyl acetate (20 mL). The organic phase is washed three times with 20 mL of saturated sodium bicarbonate solution. The aqueous phase is adjusted to pH 1 - 2 with 1N dilute hydrochloric acid, a large amount of white solid precipitates, filter by suction, wash with ice water, and dry by infrared drying to obtain 3-((3-bromo-2,4-difluorophenyl)amino)-3-oxopropanoic acid as a white solid, 8.2 g, with a yield of 93%. 1 H NMR (400 MHz, DMSO-d6) δ 12.69 (s, 1H), 10.13 (s, 1H), 7.95 - 7.86 (m, 1H), 7.31 - 7.24 (m, 1H).
[0117] Step B: Mix 3-((3-bromo-2,4-difluorophenyl)amino)-3-oxopropanoic acid (3.5 g, 15 mmol, 1.0 eq) with Eaton's reagent (CAS: 39394 - 84 - 8) (30 mL), and heat the reaction mixture at 70 °C for 5 h. After the reaction mixture is cooled, add ice water (100 mL), filter by suction, and wash the filter cake with ice water to obtain the product 7-bromo-6,8-difluoro-4-hydroxy-1,2-dihydroquinolin-2-one as a light yellow solid, 1.7 g, with a yield of 51%. 1 H NMR (300 MHz, Chloroform-d) δ 8.33 (s, 1H), 8.20 (ddd, J = 9.3, 8.4, 5.5 Hz, 1H), 7.07 - 7.01 (m, 1H), 6.09 (s, 1H).
[0118] Step C: Dissolve 7-bromo-6,8-difluoro-4-hydroxy-1,2-dihydroquinolin-2-one (2.0 g, 7.75 mmol, 1.0 eq) in phosphorus oxychloride (16.62 mL, 178.26 mmol, 23.0 eq), add N,N-diisopropylethylamine (6.75 mL, 38.75 mmol, 5.0 eq), and reflux the reaction mixture at 100 °C for 8 h. Rotate the reaction mixture to dryness, pour it into ice, then extract it three times with 30 mL of dichloromethane each time. Concentrate the organic phase and purify it by column chromatography (petroleum ether:ethyl acetate = 15:1) to obtain the product intermediate 5 as a pale yellow solid, 1.7 g; yield 72%. 1 H NMR (300 MHz, DMSO-d6) δ 8.21 (s, 1H), 8.01 (dd, J = 9.2, 2.0 Hz, 1H). EI-MS m / z: 311.88 [M+H] + .
[0119] Intermediate 6
[0120] Dissolve intermediate 5 (313 mg, 1 mmol, 1.0 eq) and N,N-diisopropylethylamine (28 mg, 1.5 mmol, 1.5 eq) in CH3CN (15 mL), add 8-Boc-3,8-diazabicyclo[3.2.1]octane (212 mg, 1 mmol, 1.0 eq), and heat the reaction mixture to 90 °C for 10 h. After the reaction is completed, add water (15 mL) to quench the reaction, then extract it three times with 15 mL of dichloromethane each time. Concentrate the organic phase and purify it by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain the product intermediate 6 as a white solid, 200 mg, yield 41%. 1 H NMR (400 MHz, DMSO-d6) δ 7.69 (dd, J = 9.3, 1.9 Hz, 1H), 7.63 (s, 1H), 4.30 - 4.22 (m, 4H), 3.09 (d, J = 12.2 Hz, 2H), 1.87 (s, 2H), 1.65 (d, J = 7.6 Hz, 2H), 1.44 (s, 9H). EI-MS m / z: 470.08 [M+H] + .
[0121] Intermediate 7
[0122] Intermediate 6 (244 mg, 0.5 mmol, 1.0 eq), 2-(8-chloro-3-((tetrahydro-2H-pyran-2-yl)oxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (195 mg, 0.5 mmol, 1.0 eq), and potassium carbonate (207 mg, 1.5 mmol, 3.0 eq) were added to dioxane (3 mL). Tetrakis(triphenylphosphine)palladium (29 mg, 0.025 mmol, 0.05 eq) and water (1 mL) were successively added, and the mixture was heated to 90 °C under nitrogen protection and reacted for 7 h. The reaction was quenched by adding water (10 mL), and then extracted three times with 25 mL of ethyl acetate each time. The organic phase was concentrated, and purified by column chromatography (petroleum ether:ethyl acetate = 12:1) to obtain Intermediate 7 as a white solid, 120 mg, with a yield of 37%. EI-MS m / z: 670.22 [M+H] + .
[0123] The preparation method of the above coupling intermediate 2-(8-chloro-3-((tetrahydro-2H-pyran-2-yl)oxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is as follows:
[0124]
[0125] A) 4-Bromo-5-chloronaphthalen-2-ol (CAS: 2454397-73-8) (105 mg, 0.4 mmol, 1.0 eq), bis(pinacolato)diboron (CAS: 73183-34-3) (203 mg, 0.8 mmol, 2.0 eq), potassium acetate (134 mg, 1.2 mmol, 3.0 eq), and ferrocenedichloropalladium (15 mg, 0.02 mmol, 0.05 eq) were dissolved in 1,4-dioxane (5 mL), and refluxed at 90 °C for 24 h under nitrogen protection. After the reaction was completed, the reaction was quenched by adding water (15 mL), extracted twice with dichloromethane (15 mL), the organic phases were combined, concentrated under reduced pressure, and purified by column chromatography (petroleum ether:ethyl acetate = 10:1) to obtain 5-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol as a white solid, 80 mg, with a yield of 66%. 1 H NMR (400 MHz, DMSO-d6) δ 10.01 (s, 1H), 7.71 (dd, J = 8.0, 1.4 Hz, 1H), 7.44 - 7.33 (m, 2H), 7.22 (d, J = 2.5 Hz, 1H), 7.18 (d, J = 2.5 Hz, 1H), 1.36 (s, 12H). EI-MS m / z: 305.10 [M+H] + .
[0126] B) 5-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol (305 mg, 1.0 mmol, 1.0 eq) and 3,4-dihydropyran (168 mg, 2.0 mmol, 2.0 eq) were dissolved in dichloromethane (4 mL), and then pyridinium 4-methylbenzenesulfonate (13 mg, 0.05 mmol, 0.05 eq) was added. The reaction was stirred at room temperature for 24 h. The reaction solution was diluted with dichloromethane (20 mL) and washed twice with saturated NaCl solution (10 mL). The organic phase was concentrated and purified by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 2-(8-chloro-3-((tetrahydro-2H-pyran-2-yl)oxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane as a white solid, 360 mg, with a yield of 92%. EI-MS m / z: 389.17 [M+H] + .
[0127] Intermediate 8
[0128] Intermediate 7 (62 mg, 0.1 mmol, 1.0 eq), 4,4-difluorocyclohexan-1-ol (13.4 mg, 0.1 mmol, 1.0 eq) and potassium carbonate (70 mg, 0.5 mmol, 5.0 eq) were added to toluene (10 mL). Tris(dibenzylideneacetone)dipalladium (3 mg, 0.005 mmol, 0.05 eq) and 1,1'-binaphthalene-2,2'-bis(diphenylphosphine) (5 mg, 0.01 mmol, 0.1 eq) were added, and the mixture was heated to 130 °C under nitrogen protection for 12 h. After the reaction was completed, water (10 mL) was added to quench the reaction, and then the mixture was extracted three times with 15 mL of ethyl acetate. The organic phase was concentrated and separated by column chromatography (petroleum ether:ethyl acetate = 2:1) to obtain Intermediate 8 as a white solid, 39 mg, with a yield of 49%. EI-MS m / z: 770.30 [M+H] + .
[0129] Compound VI
[0130] Intermediate 8 (39 mg, 0.05 mmol, 1.0 eq) was dissolved in hydrochloric acid-methanol solution (5 mL), and the mixture was stirred at room temperature for 12 h. The reaction solution was concentrated under reduced pressure, filtered by suction, the filter cake was dissolved in methanol (2 mL), saturated sodium bicarbonate solution (5 mL) was added, and then filtered by suction. The filter cake was washed with ice water and dried by infrared to obtain Compound VI as a white solid, 20 mg, with a yield of 68%. 11H NMR (400 MHz, DMSO-d6) δ 7.81 - 7.69 (m, 1H), 7.48 (d, J = 9.6 Hz, 1H), 7.33 (t, J = 7.8 Hz, 1H), 7.27 (d, J = 7.4 Hz, 2H), 7.04 (d, J = 2.5 Hz, 1H), 6.65 (s, 1H), 5.07 (s, 1H), 4.09 (d, J = 11.7 Hz, 2H), 3.52 (s, 2H), 2.97 (d, J = 11.9 Hz, 2H), 2.29 - 2.05 (m, 4H), 2.02 (dd, J = 11.8, 5.5 Hz, 4H), 1.64 (p, J = 8.5, 7.8 Hz, 4H). HRMS (ESI): calcd for C 31 H 28 ClF4N3O2 [M + H] + 586.1879, found 586.1875.
[0131] Test Example 3
[0132] Intermediate 9
[0133] Intermediate 6 (244 mg, 0.5 mmol, 1.0 eq), 4,4,5,5 - tetramethyl - 2 - (3 - ((tetrahydro - 2H - pyran - 2 - yl)oxy)naphthalen - 1 - yl)-1,3,2 - dioxaborolane (178 mg, 0.5 mmol, 1.0 eq), and potassium carbonate (207 mg, 1.5 mmol, 3.0 eq) were added to dioxane (3 mL). Tetrakis(triphenylphosphine)palladium (29 mg, 0.025 mmol, 0.05 eq) and water (1 mL) were added successively. The reaction was heated to 90 °C under nitrogen protection for 7 h. The reaction was quenched by adding water (10 mL), and then extracted three times with 25 mL of ethyl acetate each time. The organic phase was concentrated and purified by column chromatography (petroleum ether:ethyl acetate = 12:1) to obtain Intermediate 9 as a white solid, 120 mg, with a yield of 38%. EI - MS m / z: 636.26 [M + H] + .
[0134] The preparation method of 4,4,5,5 - tetramethyl - 2 - (3 - ((tetrahydro - 2H - pyran - 2 - yl)oxy)naphthalen - 1 - yl)-1,3,2 - dioxaborolane of the above coupling intermediate is as follows:
[0135]
[0136] Dissolve 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol (CAS: 2043962-01-0) (270 mg, 1.0 mmol, 1.0 eq) and 3,4-dihydropyran (168 mg, 2.0 mmol, 2.0 eq) in dichloromethane (4 mL), then add pyridinium 4-methylbenzenesulfonate (13 mg, 0.05 mmol, 0.05 eq), and stir at room temperature for 24 h. Dilute the reaction solution with dichloromethane (20 mL), wash it twice with saturated NaCl solution (10 mL) respectively, concentrate the organic phase, and separate and purify it by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 4,4,5,5-tetramethyl-2-(3-((tetrahydro-2H-pyran-2-yl)oxy)naphthalen-1-yl)-1,3,2-dioxaborolane, which is a white solid, 350 mg, with a yield of 98%. EI-MS m / z: 355.21 [M+H] + .
[0137] Intermediate 10
[0138] Add intermediate 9 (220 mg, 0.35 mmol, 1.0 eq), 4,4-difluorocyclohexan-1-ol (48 mg, 0.35 mmol, 1.0 eq), and potassium carbonate (70 mg, 0.5 mmol, 5.0 eq) to toluene (10 mL), then add tris(dibenzylideneacetone)dipalladium (10 mg, 0.02 mmol, 0.05 eq) and 1,1'-binaphthalene-2,2'-bis(diphenylphosphine) (17 mg, 0.04 mmol, 0.1 eq), and heat to 130 °C under nitrogen protection for 12 h. Quench the reaction with water (10 mL), then extract three times with 20 mL of ethyl acetate respectively. Concentrate the organic phase, and separate and purify it by column chromatography (petroleum ether:ethyl acetate = 12:1) to obtain intermediate 10, which is a white solid, 170 mg, with a yield of 66%. 1 H NMR (300 MHz, DMSO-d6) δ 7.93 (d, J = 8.3 Hz, 1H), 7.71 - 7.61 (m, 2H), 7.52 (ddd, J = 8.2, 6.1, 2.0 Hz, 1H), 7.35 (dt, J = 9.3, 2.3 Hz, 3H), 6.79 (s, 1H), 5.72 (s, 1H), 5.12 (s, 1H), 4.26 (s, 4H), 3.93 - 3.78 (m, 1H), 3.75 - 3.58 (m, 1H), 3.05 (d, J = 12.2 Hz, 2H), 2.32 - 1.52 (m, 20H), 1.43 (s, 9H). EI-MS m / z: 736.34 [M+H] + .
[0139] Compound VII
[0140] Dissolve Intermediate 10 (39 mg, 0.23 mmol, 1.0 eq) in hydrochloric acid - methanol solution (5 mL), stir at room temperature for 12 h, concentrate the reaction solution under reduced pressure, filter by suction, dissolve the filter cake in methanol (2 mL), add saturated sodium bicarbonate solution (5 mL), filter by suction, wash the filter cake with ice water, and dry by infrared to obtain Compound VII as a white solid, 60 mg, with a yield of 47%. The 1 1H NMR (400 MHz, DMSO - d6) δ 10.02 (s, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.62 (dd, J = 9.8, 1.5 Hz, 1H), 7.44 (ddd, J = 8.1, 6.5, 1.3 Hz, 1H), 7.34 - 7.27 (m, 2H), 7.23 (ddd, J = 8.2, 6.6, 1.2 Hz, 1H), 7.13 (d, J = 2.4 Hz, 1H), 6.70 (s, 1H), 5.11 (s, 1H), 4.12 (d, J = 12.0 Hz, 2H), 3.53 (s, 2H), 2.99 (d, J = 11.8 Hz, 2H), 2.30 - 1.95 (m, 8H), 1.65 (tt, J = 10.9, 7.7, 6.5 Hz, 4H). HRMS (ESI): calcd for C 31 H 29 F4N3O2[M + H] + 552.2269, found 552.2270.
[0141] Test Example 4
[0142]
[0143] Intermediate A
[0144] 1 - Bromo - 8 - chloronaphthalene (1.2 g, 5.0 mmol, 1.0 eq), bis(pinacolato)diboron (1.4 g, 5.5 mmol, 1.1 eq), and potassium acetate (1.5 g, 15 mmol, 3.0 eq), palladium(II) dichloride ferrocene (183 mg, 0.25 mmol, 0.05 eq), were dissolved in 1,4 - dioxane (25 mL). After displacing nitrogen, the mixture was refluxed at 90 °C for 24 h. After the reaction was complete, the reaction mixture was quenched by adding water (15 mL) and extracted with dichloromethane ((15 mL × 2)). The organic phase was concentrated and purified by column chromatography (petroleum ether:ethyl acetate = 10:1) to obtain 900 mg of white solid 2 - (8 - chloronaphthalen - 1 - yl) - 4,4,5,5 - tetramethyl - 1,3,2 - dioxaborolane, with a yield of 62.4%.
[0145] Intermediate 11
[0146] Dissolve 7-bromo-6,8-difluoro-4-hydroxy-1,2-dihydroquinolin-2-one (2.76 g, 10 mmol, 1.0 eq, Intermediate 1-0) in phosphorus oxychloride (21.7 mL, 230 mmol, 23.0 eq), then add N,N-diisopropylethylamine (8.7 mL, 50 mmol, 5.0 eq). The mixture is refluxed at 100 °C for 8 h. The reaction mixture is concentrated by rotary evaporation, poured into ice, and extracted with dichloromethane (30 ml × 3). The organic phase is concentrated and purified by column chromatography (petroleum ether:ethyl acetate = 15:1) to obtain 2.22 g of 7-bromo-2,4-dichloro-6,8-difluoroquinoline as a pale yellow powder; the yield is 70.9%, R f : 0.60 (petroleum ether:ethyl acetate = 6:1). The 1 1H NMR (300 MHz, DMSO-d6) δ 8.21 (s, 1H), 8.01 (dd, J = 9.2, 2.0 Hz, 1H).
[0147] Intermediate 12
[0148] A solution of Intermediate 11 (313 mg, 1 mmol, 1.0 eq) and N,N-diisopropylethylamine (28 mg, 1.5 mmol, 1.5 eq) in CH3CN (15 mL) is mixed, and then 8-Boc-3,8-diazabicyclo[3.2.1]octane (212 mg, 1 mmol, 1.0 eq) is added. The mixture is heated to 90 °C and reacted for 10 h. After the reaction is complete, water (15 mL) is added to the reaction solution to quench the reaction, and the mixture is extracted with dichloromethane (15 mL × 2). The organic phase is concentrated and separated by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 200 mg of the product (1R,5S)-3-(7-bromo-2-chloro-6,8-difluoroquinolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester as a white solid; the yield is 40.9%, R f : 0.50 (petroleum ether:ethyl acetate = 10:1). The 1 1H NMR (400 MHz, DMSO-d6) δ 7.69 (dd, J = 9.3, 1.9 Hz, 1H), 7.63 (s, 1H), 4.30 - 4.22 (m, 4H), 3.09 (d, J = 12.2 Hz, 2H), 1.87 (s, 2H), 1.65 (d, J = 7.6 Hz, 2H), 1.44 (s, 9H).
[0149] Intermediate 13
[0150] Intermediate A (49 mg, 0.1 mmol, 1.0 eq) and Intermediate 12 (29 mg, 0.1 mmol, 1.0 eq), potassium carbonate (41 mg, 0.3 mmol, 3.0 eq) were dissolved in 1,4-dioxane (3 mL), then tetrakis(triphenylphosphine)palladium(0) (29 mg, 0.025 mmol, 0.05 eq) was added, and finally water (1 mL) was added. After displacing nitrogen, the mixture was heated to 90 °C and reacted for 7.0 h. The mixed reaction solution was quenched by adding water (10 mL) and extracted twice with ethyl acetate (15 mL). The organic phase was concentrated and purified by column chromatography (petroleum ether:ethyl acetate = 12:1) to obtain 25 mg of tert-butyl (1R,5S)-3-(2-chloro-7-(8-chloronaphthalen-1-yl)-6,8-difluoroquinolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate as a white solid, with a yield of 43.8%, R f : 0.5 (petroleum ether:ethyl acetate = 3:1).
[0151] Intermediate 14
[0152] Intermediate 13 (57 mg, 0.1 mmol, 1.0 eq) and (1-methylpiperidin-3-yl)methanol (16 mg, 0.12 mmol, 1.2 eq), sodium hydride (12 mg, 0.5 mmol, 5.0 eq) were dissolved in toluene and stirred for 5 minutes, then tris(dibenzylideneacetone)dipalladium(0) (5 mg, 0.005 mmol, 0.05 eq) and 1,1'-binaphthalene-2,2'-bis(diphenylphosphine) (3 mg, 0.005 mmol, 0.05 eq) were added. After displacing nitrogen, the mixture was heated to 130 °C and reacted for 12 h. After the reaction was complete, the reaction solution was quenched by adding water (10 mL) and extracted twice with ethyl acetate (20 mL). After concentration, it was separated by column chromatography (petroleum ether:ethyl acetate = 12:1) to obtain 35 mg of tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-6,8-difluoro-2-((1-methylpiperidin-3-yl)methoxy)quinolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate as a white solid, with a yield of 53.8%, R f : 0.4 (petroleum ether:ethyl acetate = 2:1).
[0153] Compound VIII
[0154] Intermediate 14 (33 mg, 0.05 mmol, 1.0 eq) was dissolved in hydrochloric acid - ethyl acetate solution (3 mL) and stirred at room temperature for 4.0 h. After the reaction was complete, it was filtered, and the filter cake was washed twice with petroleum ether:ethyl acetate = 4:1 (4 mL). Yellow solid 4 - ((1R,5S)-3,8 - diazabicyclo[3.2.1]octan - 3 - yl)-7-(8 - chloronaphthalen - 1 - yl)-6,8 - difluoro - 2 - ((1 - methylpiperidin - 3 - yl)methoxy)quinoline, 15 mg, yield 53.3%, EI - MS m / z of this compound: 563.1 [M + H] + .
[0155] Test Example 5
[0156]
[0157] Intermediate A was prepared in the same way as in Test Example 4.
[0158] Intermediate 15
[0159] 7 - Bromo - 8 - fluoro - 4 - hydroxy - 1,2 - dihydroquinolin - 2 - one (2.0 g, 7.75 mmol, 1.0 eq, Intermediate 2 - 0) was dissolved in phosphorus oxychloride (16.62 mL, 178.26 mmol, 23.0 eq), and then N,N - diisopropylethylamine (6.75 mL, 38.75 mmol, 5.0 eq) was added. The mixture was refluxed at 100 °C for 8 h. The reaction mixture was evaporated to dryness, poured into ice, and extracted with dichloromethane (20 mL × 3). The organic phase was concentrated and purified by column chromatography (petroleum ether:ethyl acetate = 15:1) to obtain 1.66 g of pale yellow powder 7 - bromo - 2,4 - dichloro - 8 - fluoroquinoline; yield 72.6%, R f : 0.60 (petroleum ether:ethyl acetate = 6:1), the 1 1H NMR (300 MHz, Chloroform - d) δ 7.91 (d, J = 9.1 Hz, 1H), 7.79 (dd, J = 9.1, 5.9 Hz, 1H), 7.62 (s, 1H).
[0160] Intermediate 16
[0161] Intermediate 15 (1.0 g, 3.39 mmol, 1.0 eq) was mixed with a CH3CN solution (15 mL) of N,N-diisopropylethylamine (3.54 mL, 23.73 mmol, 7.0 eq), and then 8-Boc-3,8-diazabicyclo[3.2.1]octane (791.84 mg, 3.73 mmol, 1.1 eq) was added. The reaction was stirred at room temperature for 48.0 h. The reaction mixture was added with water (15 mL) and extracted with dichloromethane (15 mL × 3). The organic phase was dried by rotation, ethyl acetate was added, and the filtered cake was a white solid of 420 mg. The filtrate was recrystallized to obtain a solid of 200 mg. The remaining filtrate was separated by column chromatography (petroleum ether:ethyl acetate = 5:1) to obtain 190 mg of the product. A total of 817 mg of white solid 3-(7-bromo-2-chloro-8-fluoroquinolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid 2-methylpropyl-2-yl ester was obtained, with a yield of 51.1%, R f : 0.50 (petroleum ether:ethyl acetate = 10:1), for this compound 1 1H NMR (300 MHz, Chloroform-d) δ 7.63 (dd, J = 9.0, 1.5 Hz, 1H), 7.36 (dd, J = 8.9, 6.0 Hz, 1H), 7.05 (s, 1H), 4.41 (s, 2H), 3.28 (s, 2H), 2.03 - 1.93 (m, 2H), 1.76 (d, J = 8.9 Hz, 4H), 1.49 (s, 10H).
[0162] Intermediate 17
[0163] Intermediate A (35 mg, 0.12 mmol, 1.2 eq) and intermediate 16 (47 mg, 0.1 mmol, 1.0 eq), cesium carbonate (65 mg, 0.2 mmol, 2.0 eq) were dissolved in 1,4-dioxane (3 mL), then tetrakis(triphenylphosphine)palladium (6 mg, 0.005 mmol, 0.05 eq) was added, and finally water (1 mL) was added. After displacing nitrogen, the reaction was heated to 90 °C for 7.0 h. The mixed reaction solution was quenched with water (10 mL) and extracted twice with ethyl acetate (15 mL). The organic phase was concentrated and separated by column chromatography (petroleum ether:ethyl acetate = 12:1) to obtain 35 mg of white solid tert-butyl (1R,5S)-3-(2-chloro-7-(8-chloronaphthalen-1-yl)-8-fluoroquinolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate, with a yield of 63.4%, R f : 0.5 (petroleum ether:ethyl acetate = 3:1).
[0164] Intermediate 18
[0165] Intermediate 18 (55 mg, 0.1 mmol, 1.0 eq) and (1-methylpiperidin-3-yl)methanol (16 mg, 0.12 mmol, 1.2 eq), sodium hydride (12 mg, 0.5 mmol, 5.0 eq) were dissolved in toluene and stirred for 5 minutes. Then tris(dibenzylideneacetone)dipalladium (5 mg, 0.005 mmol, 0.05 eq) and 1,1'-binaphthalene-2,2'-bis(diphenylphosphine) (3 mg, 0.005 mmol, 0.05 eq) were added. After replacing nitrogen, the mixture was heated to 130 °C and reacted for 12 h. After the reaction was complete, the reaction solution was quenched with water (10 mL) and extracted twice with ethyl acetate (20 mL). After concentration, it was separated by column chromatography (petroleum ether:ethyl acetate = 12:1) to obtain the white solid tert-butyl (1R,5S)-3-(7-(8-chloronaphthalen-1-yl)-8-fluoro-2-((1-methylpiperidin-3-yl)methoxy)quinolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate, 45 mg, yield 69.7%, R f : 0.4 (petroleum ether:ethyl acetate = 2:1).
[0166] Compound IX
[0167] Intermediate 18 (32 mg, 0.05 mmol, 1.0 eq) was dissolved in hydrochloric acid-ethyl acetate solution (3 mL) and stirred at room temperature for 4.0 h. After the reaction was complete, it was filtered, and the filter cake was washed twice with petroleum ether:ethyl acetate = 4:1 (4 mL). 4-((1R,5S)-3,8-Diazabicyclo[3.2.1]oct-3-yl)-7-(8-chloronaphthalen-1-yl)-8-fluoro-2-((1-methylpiperidin-3-yl)methoxy)quinoline was obtained, 15 mg, yield 55.0%, and the EI-MS m / z of this compound was: 545.1 [M+H] + 。
[0168] Comparative Example 1
[0169] The structural formula of Compound 4 is:
[0170]
[0171] Its preparation method is as follows:
[0172]
[0173] The specific preparation reaction process is the same as that in Test Example 4.
[0174] Comparative Example 2
[0175] The structural formula of Compound 5 is:
[0176]
[0177] Its preparation method:
[0178]
[0179] The specific preparation reaction process is the same as that in Test Example 5.
[0180] Performance test
[0181] Perform cell experiments on the compounds in the above-mentioned examples and comparative examples, and observe the killing effect on cells.
[0182] Specific experimental process:
[0183] Experimental Example 1
[0184] As Figure 1 shown, Figure 1 For the cell killing curve of Compound V in Test Example 1, the inflection point of the curve occurs at a concentration (about 1 μM) on G12D cells, which is less than the concentrations of control cells (HUVEC, human umbilical vein endothelial cells) and G12V cells (10 μM), indicating that a smaller dose of Compound V can more effectively kill and inhibit G12D cells, and higher concentrations are required for G12V and normal cells to have a reaction; in G12D cells, when the OD value drops to half, the corresponding concentration is approximately above 10 μM and does not exceed 11 μM. Compound V in Test Example 1 has a killing effect on all three types of cells, and the onset time is shorter, and the killing and inhibitory effect on G12D is better than that on normal cells and G12V cells.
[0185] While Figure 2 the cell killing curve of Sotorasib shows that the killing effect of Sotorasib on the three cells is not obvious, indicating that Sotorasib in Comparative Example 2 has no obvious killing or inhibitory effect on cells.
[0187] (2) Perform cell experiments on the compounds in the examples of this application and the KRAS G12D inhibitor MRTX1133, and observe the killing effect on cancer cells. The results are shown in Figures 3 to 6 .
[0188] As Figures 3 to 6 shown, the inhibition of MRTX1133 on AGS cells proceeds slowly, that is, MRTX1133 is concentration-dependent, while Compounds V, VI, and VII of this application suddenly reach an inhibition rate of 100% at a certain concentration point, indicating that the mechanism of action of the compounds in this application and MRTX1133 on cancer cells is completely different.
[0189] Experimental Example 2
[0190] KRAS G12D & SOS1 binding experiment
[0191] Add 2 μL of the compound prepared at different concentrations, 4 μL of Tag1-SOS1 protein, and 4 μL of Tag2-KRAS-G12D protein to a 96- or 384-well plate, and incubate at room temperature for 15 minutes. Add 10 μL of premixed anti-Tag1-Tb3 + and anti-Tag2-XL665. Seal the plate and incubate at 4 °C for 3 hours to overnight. Remove the plate sealer and read the signal values at 665 nM / 615 nM on an ELISA reader compatible with Compound VIII is as shown in Figure 7 , and compound IX is as shown in Figure 8 . The IC 50 values were fitted using GraphPad Prism 8, as shown in Table 1.
[0192] Table 1: Inhibitory activity of compounds against KRAS G12D binding
[0193] Experimental Example 3
[0194] Cell viability assay by CTL method
[0195] Seed AGS (KARS G12D ) or MKN1 (KARS WT ) cells into a 96-well white cell culture plate at a density of approximately 2000 cells / well, with 100 μL of cell suspension per well, and allow them to adhere for 12 - 14 h; remove the culture medium in the 96-well plate, add the culture medium containing different concentrations of the drug, with 3 replicates for each concentration, and incubate for 72 h; drug concentration settings: AGS (KARS G12D ): 10 μM + 3 μM starting with 9 or 12 three-fold dilution concentration gradients); MKN1 (KARS WT ): 10 μM + 3 μM + 1 μM. Take out the cell culture plate and equilibrate at room temperature for 10 min; add 100 μL of CellTiter-Lumi luminescent reagent (CellTiter-Lumi TM Luminescent Cell Viability Assay Kit) to each well, shake at room temperature for 2 min, and incubate at room temperature for 10 min; detect the relative fluorescence value of chemiluminescence (RLU, relative luminescence units); calculate the inhibition rate based on the RLU value of the blank well, and use Graphpad 8.0.1 software to fit the IC 50Values are shown in Table 2.
[0196] Table 2: CTL method cell activity of compounds
[0197] The activity comparison results are shown in Table 1 and Table 2. It can be found that under the condition that other groups are the same, only Compound VIII and Compound IX in the present invention have good KRAS G12D inhibitory activity. When other groups are on the quinoline nucleus, such as ((S)-1-methylpyrrolidin-2-yl)methyloxy, (1-methylpiperidin-4-yl)methyloxy, etc., the inhibitory activity against KRAS G12D decreases significantly.
[0198] The above are only the preferred embodiments of the present application and are not intended to limit the present application. Any modifications, equivalent replacements or improvements made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims
1. A quinoline compound, characterized in that, The quinoline compounds include at least one of the chemical formulas shown in Formula I, and pharmaceutically acceptable salts thereof: Among them, R 1 , R 3 and R 4 independently include H, halogen, oxygen-containing group, nitrogen-containing group, phosphorus-containing group, sulfur-containing group or unsaturated carbon-carbon bond; R 2 includes alkyl group with C1-C 10 , alkenyl group with C2-C 10 , alkynyl group with C2-C 10 , cycloalkyl group with C3-C 10 , heterocycloalkyl group with C2-C 10 , aryl group with C6-C 10 or heteroaryl group with C5-C 10 , with or without substituents.
2. The quinoline compound according to claim 1, characterized in that, The oxygen-containing group includes a hydroxyl group, an ether group, a carboxyl group, an ester group, an acyl halide group, an aldehyde group or a ketone group; the nitrogen-containing group includes an amino group, a cyano group, an imino group, a nitro group, an amide group or a cyanate group; the phosphorus-containing group includes a phosphino group, a phosphoric acid group, a phosphate group, a phosphite group or a phosphite ester group; the sulfur-containing group includes a mercapto group, a thioether group, a sulfonic acid group, a sulfonate group or a disulfide bond.
3. The quinoline compound according to claim 1, wherein R 1 selected from halogen; R 3 selected from halogen or an oxygen-containing group; R 4 selected from hydrogen, an oxygen-containing group or a nitrogen-containing group; R 2 selected from a C3-C 10 cycloalkyl or a C2-C 10 heterocycloalkyl with or without substituents.
4. The quinoline compound according to claim 1, characterized in that, The substituent includes a halogen, an alkyl group having 1 to 3 carbon atoms, an amino group, a hydroxyl group, an ether group, an ester group, an aldehyde group or a ketone group.
5. The quinoline compound according to claim 1, wherein R 1 、R 2 、R 3 and R 4 The quantity of may be one or more; When there are multiple Rs 1 the multiple Rs 1 may be completely identical, partially identical, or completely different.
6. The quinoline compound according to claim 4, wherein When there are multiple Rs 1 , the multiple Rs 1 are exactly the same; when there are multiple Rs 3 , the multiple Rs 3 are completely different.
7. The quinoline compound according to claim 6, characterized in that, The R 1 is F or Cl; The R 2 is a C4-C6 cycloalkyl or C4-C6 hetero cycloalkyl with or without substituents. Preferably, R 2 is The R 3 is at least one of OH, alkynyl, and Cl.
8. The quinoline-based compound according to claim 7, characterized in that, The quinoline-based compounds include:
9. A method for preparing the quinoline compound according to any one of claims 1 to 8, characterized in that, including: (1) React with to produce (2) First, react with to form Then, react with to form Or, first react with Then, react with (3) Remove R under acidic or basic conditions 5 to generate the quinoline compounds; Among them, X is a halogen, preferably bromine or iodine; R 5 is an amino protecting group, preferably selected from tert-butoxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc); R 6 is selected from hydrogen, methyl or two Rs 6 are connected to the corresponding oxygen or boron atom to form a 5- to 6-membered ring, such as 10. A preparation, characterized in that, including the quinoline compounds described in any one of Claims 1 to 8.
11. Use of the preparation according to Claim 10 in the preparation of a medicament for treating cerebral arteriovenous malformation.
12. Use of the quinoline compound according to Claim 10 or a pharmaceutically acceptable salt thereof in the preparation of a KRAS G12D inhibitor and in the preparation of a medicament for a disease related to a KRAS G12D gene mutation; Preferably, the disease is selected from pancreatic cancer, non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, colon cancer, colorectal cancer, thyroid cancer, embryonal rhabdomyosarcoma, cutaneous granular cell tumor, melanoma, liver cancer, rectal cancer, bladder cancer, throat cancer, breast cancer, prostate cancer, glioblastoma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, kidney cancer, skin cancer, lymphoma, gastric cancer, acute myeloid leukemia, myelofibrosis, B-cell lymphoma, monocytic leukemia, splenomegalic polycythemia, hypereosinophilic syndrome multiple myeloma and other various solid tumors and hematological tumors with a KRAS G12D gene mutation.
Citation Information
Patent Citations
Application of lovastatin or pharmaceutically acceptable salt thereof in preparation of drugs for treating cerebral arteriovenous malformation
CN111568898A
Application of thalidomide and thalidomide derivative
CN111658647A
